LEADER 02008nam2 22004093i 450 001 IEI0176381 005 20251003044200.0 010 $a8806157442 010 $a9788806157449$bristampa 100 $a20170103d2001 ||||0itac50 ba 101 | $aita$cita 102 $ait 181 1$6z01$ai $bxxxe 182 1$6z01$an 183 1$6z01$anc$2RDAcarrier 200 1 $aˆ17: Il ‰Parlamento$fa cura di Luciano Violante$gcon la collaborazione di Francesca Piazza 210 $aTorino$cEinaudi$d2001 215 $aLXVII, 1442 p.$cill.$d22 cm 300 $aIn custodia 461 1$1001CFI0012299$12001 $aStoria d'Italia. Annali$v17 500 11$aˆIl ‰Parlamento$3UM10252438$983688 676 $a328.45$9Potere legislativo. Italia$v12 676 $a328.45$9PROCESSO LEGISLATIVO ITALIANO$v21 676 $a328.4509$9POTERE LEGISLATIVO ITALIANO. STORIA$v21 676 $a328.4509$9PROCESSO LEGISLATIVO ITALIANO. Trattamento storico$v22 676 $a945$9STORIA. ITALIA$v21 686 $aIT/X422.1$cPARLAMENTO ITALIA$2R 702 1$aViolante$b, Luciano$f <1941- >$3CFIV050915 702 1$aPiazza$b, Francesca$f <1969- >$3IEIV061000 801 3$aIT$bIT-000000$c20170103 850 $aIT-BN0095 $aIT-SA0112 $aIT-AV0175 $aIT-NA0299 $aIT-AV0001 $aIT-AV0003 $aIT-AV0007 $aIT-NA0322 $aIT-NA0079 $aIT-NA0070 $aIT-NA0120 $aIT-SA0111 $aIT-NA0256 $aIT-NA0230 $aIT-NA0452 $aIT-AV0045 $aIT-NA0681 $aIT-NA0097 901 $bNAP AG$cII $n$ 912 $aIEI0176381 950 2$aBiblioteca Centralizzata di Ateneo$cv. 1-9 (2. copia); 10-22$d 01POZZO LIB.STO ITA 5$e 0101 0060060295E VMA (00017 v. 17 (6. Rist. 2004)$fB $h20210517$i20210517 977 $a 01$a 84$a 90$a AG$a AL$a AR$a AV$a BF$a BN$a BU$a CR$a CS$a ID$a IR$a IS$a MV$a PM$a SP 996 $aParlamento$983688 997 $aUNISANNIO LEADER 12331nam 2200709 a 450 001 9910815905603321 005 20251116171640.0 010 $a1-283-40610-1 010 $a9786613406101 010 $a1-118-32149-9 010 $a1-4443-6099-X 035 $a(CKB)2670000000139931 035 $a(EBL)832458 035 $a(OCoLC)769928290 035 $a(SSID)ssj0000575884 035 $a(PQKBManifestationID)11349253 035 $a(PQKBTitleCode)TC0000575884 035 $a(PQKBWorkID)10553955 035 $a(PQKB)10610502 035 $a(MiAaPQ)EBC832458 035 $a(Au-PeEL)EBL832458 035 $a(CaPaEBR)ebr10630587 035 $a(CaONFJC)MIL340610 035 $a(PPN)161619274 035 $a(BIP)46446252 035 $a(BIP)36269907 035 $a(EXLCZ)992670000000139931 100 $a20110822d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aFungal infection $ediagnosis and management /$fMalcolm D. Richardson, David W. Warnock 205 $a4th ed. 210 $aChichester, West Sussex, U.K. $cWiley-Blackwell$d2012 215 $a1 online resource (477 p.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 08$a1-4443-6102-3 311 08$a1-4051-7056-5 320 $aIncludes bibliographical references and index. 327 $aIntro -- Fungal Infection : DIAGNOSIS AND MANAGEMENT -- Contents -- Preface to the fourth edition -- Preface to the first edition -- Acknowledgements -- 1 Introduction -- 1.1 The nature of fungi -- 1.2 Classification and nomenclature of fungi and fungal diseases -- 1.3 Fungi as human pathogens -- 1.3.1 The superficial mycoses -- 1.3.2 The subcutaneous mycoses -- 1.3.3 The systemic mycoses -- 1.4 The changing pattern of fungal infection -- 1.5 New directions in diagnosis -- 1.6 New directions in treatment and prevention -- Further reading -- 2 Laboratory diagnosis of fungal infection -- 2.1 Introduction -- 2.2 Collection of specimens -- 2.2.1 Skin, nails and hair -- 2.2.2 Mucous membranes -- 2.2.3 Ear -- 2.2.4 Eye -- 2.2.5 Blood -- 2.2.6 Cerebrospinal fluid -- 2.2.7 Urine -- 2.2.8 Other fluids -- 2.2.9 Lower respiratory tract specimens -- 2.2.10 Pus -- 2.2.11 Bone marrow -- 2.2.12 Tissue -- 2.2.13 Medical devices -- 2.3 Specimens for serological tests -- 2.4 Specimens for antifungal drug level determinations -- 2.5 Transport of specimens -- 2.6 Interpretation of laboratory test results -- 2.6.1 Direct microscopic examination -- 2.6.2 Histopathological examination -- 2.6.3 Immunohistochemistry -- 2.6.4 In situ hybridization -- 2.6.5 Culture -- 2.6.6 Fungal identification -- 2.6.7 Molecular identification -- 2.6.8 Serological tests -- 2.6.9 ?-D-glucan detection -- 2.7 Molecular diagnosis of fungal infection -- Further reading -- 3 Antifungal drugs -- 3.1 Introduction -- 3.2 Allylamines -- 3.2.1 Mechanism of action -- 3.3 Terbinafine -- 3.3.1 Spectrum of activity -- 3.3.2 Acquired resistance -- 3.3.3 Pharmacokinetics -- 3.3.4 Pharmaceutics -- 3.3.5 Therapeutic use -- 3.3.6 Mode of administration -- 3.3.7 Drug interactions -- 3.3.8 Toxicity and adverse reactions -- 3.4 Other allylamine compounds for topical administration -- 3.4.1 Naftifine. 327 $a3.5 Azoles -- 3.5.1 Mechanism of action -- 3.5.2 Acquired resistance -- 3.5.3 Drug interactions -- 3.6 Fluconazole -- 3.6.1 Spectrum of activity -- 3.6.2 Acquired resistance -- 3.6.3 Pharmacokinetics -- 3.6.4 Pharmaceutics -- 3.6.5 Therapeutic use -- 3.6.6 Mode of administration -- 3.6.7 Drug interactions -- 3.6.8 Toxicity and adverse reactions -- 3.7 Itraconazole -- 3.7.1 Spectrum of activity -- 3.7.2 Acquired resistance -- 3.7.3 Pharmacokinetics -- 3.7.4 Pharmaceutics -- 3.7.5 Therapeutic use -- 3.7.6 Mode of administration -- 3.7.7 Drug interactions -- 3.7.8 Toxicity and adverse reactions -- 3.8 Ketoconazole -- 3.8.1 Spectrum of activity -- 3.8.2 Acquired resistance -- 3.8.3 Pharmacokinetics -- 3.8.4 Pharmaceutics -- 3.8.5 Therapeutic use -- 3.8.6 Mode of administration -- 3.8.7 Drug interactions -- 3.8.8 Toxicity and adverse reactions -- 3.9 Posaconazole -- 3.9.1 Spectrum of activity -- 3.9.2 Acquired resistance -- 3.9.3 Pharmacokinetics -- 3.9.4 Pharmaceutics -- 3.9.5 Therapeutic use -- 3.9.6 Mode of administration -- 3.9.7 Drug interactions -- 3.9.8 Toxicity and adverse reactions -- 3.10 Voriconazole -- 3.10.1 Spectrum of activity -- 3.10.2 Acquired resistance -- 3.10.3 Pharmacokinetics -- 3.10.4 Pharmaceutics -- 3.10.5 Therapeutic use -- 3.10.6 Mode of administration -- 3.10.7 Drug interactions -- 3.10.8 Toxicity and adverse reactions -- 3.11 Other imidazole compounds for topical administration -- 3.11.1 Bifonazole -- 3.11.2 Butoconazole -- 3.11.3 Clotrimazole -- 3.11.4 Econazole nitrate -- 3.11.5 Fenticonazole nitrate -- 3.11.6 Isoconazole nitrate -- 3.11.7 Miconazole nitrate -- 3.11.8 Oxiconazole -- 3.11.9 Sertaconazole nitrate -- 3.11.10 Sulconazole nitrate -- 3.11.11 Terconazole -- 3.11.12 Tioconazole -- 3.12 Echinocandins -- 3.12.1 Mechanism of action -- 3.12.2 Spectrum of activity -- 3.12.3 Acquired resistance -- 3.12.4 Drug interactions. 327 $a3.13 Anidulafungin -- 3.13.1 Pharmacokinetics -- 3.13.2 Pharmaceutics -- 3.13.3 Therapeutic use -- 3.13.4 Mode of administration -- 3.13.5 Drug interactions -- 3.13.6 Toxicity and adverse reactions -- 3.14 Caspofungin -- 3.14.1 Pharmacokinetics -- 3.14.2 Pharmaceutics -- 3.14.3 Therapeutic use -- 3.14.4 Mode of administration -- 3.14.5 Drug interactions -- 3.14.6 Toxicity and adverse reactions -- 3.15 Micafungin -- 3.15.1 Pharmacokinetics -- 3.15.2 Pharmaceutics -- 3.15.3 Therapeutic use -- 3.15.4 Mode of administration -- 3.15.5 Drug interactions -- 3.15.6 Toxicity and adverse reactions -- 3.16 Polyenes -- 3.16.1 Mechanism of action -- 3.17 Amphotericin B -- 3.17.1 Spectrum of activity -- 3.17.2 Acquired resistance -- 3.17.3 Pharmacokinetics -- 3.17.4 Pharmaceutics -- 3.17.5 Therapeutic use -- 3.17.6 Mode of administration -- 3.17.7 Drug interactions -- 3.17.8 Toxicity and adverse reactions -- 3.18 Other polyene compounds for topical administration -- 3.18.1 Natamycin -- 3.18.2 Nystatin -- 3.19 Flucytosine -- 3.19.1 Mechanism of action -- 3.19.2 Spectrum of activity -- 3.19.3 Acquired resistance -- 3.19.4 Pharmacokinetics -- 3.19.5 Pharmaceutics -- 3.19.6 Therapeutic use -- 3.19.7 Mode of administration -- 3.19.8 Drug interactions -- 3.19.9 Toxicity and adverse reactions -- 3.20 Griseofulvin -- 3.20.1 Mechanism of action -- 3.20.2 Spectrum of activity -- 3.20.3 Acquired resistance -- 3.20.4 Pharmacokinetics -- 3.20.5 Pharmaceutics -- 3.20.6 Therapeutic use -- 3.20.7 Mode of administration -- 3.20.8 Drug interactions -- 3.20.9 Toxicity and adverse reactions -- 3.21 Other miscellaneous compounds for topical administration -- 3.21.1 Amorolfine hydrochloride -- 3.21.2 Butenafine hydrochloride -- 3.21.3 Ciclopiroxolamine -- 3.21.4 Haloprogin -- 3.21.5 Tolnaftate -- 3.22 Prophylactic treatment for prevention of fungal infection. 327 $a3.23 Empirical treatment of suspected fungal infection in the neutropenic patient -- 3.24 Pre-emptive antifungal treatment -- 3.25 Combination antifungal treatment of invasive fungal infections -- 3.26 Laboratory monitoring -- 3.26.1 Antifungal drug susceptibility testing -- 3.26.2 Monitoring of blood concentrations of antifungal drugs -- Further reading -- 4 Dermatophytosis -- 4.1 Introduction -- 4.2 The causal organisms and their habitat -- 4.3 Epidemiology -- 4.4 Laboratory diagnosis of dermatophytosis -- 4.5 Tinea capitis -- 4.5.1 Definition -- 4.5.2 Geographical distribution -- 4.5.3 Causal organisms -- 4.5.4 Epidemiology -- 4.5.5 Clinical manifestations -- 4.5.6 Differential diagnosis -- 4.5.7 Essential investigations and their interpretation -- 4.5.8 Management -- 4.5.9 Prevention -- 4.6 Tinea corporis -- 4.6.1 Definition -- 4.6.2 Geographical distribution -- 4.6.3 Causal organisms -- 4.6.4 Epidemiology -- 4.6.5 Clinical manifestations -- 4.6.6 Differential diagnosis -- 4.6.7 Essential investigations and their interpretation -- 4.6.8 Management -- 4.6.9 Prevention -- 4.7 Tinea cruris -- 4.7.1 Definition -- 4.7.2 Geographical distribution -- 4.7.3 Causal organisms -- 4.7.4 Epidemiology -- 4.7.5 Clinical manifestations -- 4.7.6 Differential diagnosis -- 4.7.7 Essential investigations and their interpretation -- 4.7.8 Management -- 4.7.9 Prevention -- 4.8 Tinea pedis -- 4.8.1 Definition -- 4.8.2 Geographical distribution -- 4.8.3 Causal organisms -- 4.8.4 Epidemiology -- 4.8.5 Clinical manifestations -- 4.8.6 Differential diagnosis -- 4.8.7 Essential investigations and their interpretation -- 4.8.8 Management -- 4.8.9 Prevention -- 4.9 Tinea manuum -- 4.9.1 Definition -- 4.9.2 Geographical distribution -- 4.9.3 Causal organisms -- 4.9.4 Epidemiology -- 4.9.5 Clinical manifestations -- 4.9.6 Differential diagnosis. 327 $a4.9.7 Essential investigations and their interpretation -- 4.9.8 Management -- 4.9.9 Prevention -- 4.10 Tinea unguium -- 4.10.1 Definition -- 4.10.2 Geographical distribution -- 4.10.3 Causal organisms -- 4.10.4 Epidemiology -- 4.10.5 Clinical manifestations -- 4.10.6 Differential diagnosis -- 4.10.7 Essential investigations and their interpretation -- 4.10.8 Management -- 4.10.9 Prevention -- Further reading -- 5 Superficial candidosis -- 5.1 Definition -- 5.2 Geographical distribution -- 5.3 The causal organisms and their habitat -- 5.4 Epidemiology -- 5.5 Clinical manifestations -- 5.5.1 Oropharyngeal candidosis -- 5.5.2 Vaginal candidosis -- 5.5.3 Penile candidosis -- 5.5.4 Cutaneous candidosis -- 5.5.5 Candida nail infection -- 5.5.6 Chronic mucocutaneous candidosis -- 5.6 Essential investigations and their interpretation -- 5.7 Management -- 5.7.1 Oropharyngeal candidosis -- 5.7.2 Vaginal candidosis -- 5.7.3 Penile candidosis -- 5.7.4 Cutaneous candidosis -- 5.7.5 Candida nail infection -- 5.7.6 Chronic mucocutaneous candidosis -- 5.8 Prevention -- Further reading -- 6 Other cutaneous fungal infections -- 6.1 Pityriasis versicolor -- 6.1.1 Definition -- 6.1.2 Geographical distribution -- 6.1.3 The causal organisms and their habitat -- 6.1.4 Epidemiology -- 6.1.5 Clinical manifestations -- 6.1.6 Differential diagnosis -- 6.1.7 Essential investigations and their interpretation -- 6.1.8 Management -- 6.2 Other Malassezia infections -- 6.2.1 Malassezia folliculitis -- 6.2.2 Seborrhoeic dermatitis -- 6.3 Piedra -- 6.4 White piedra -- 6.4.1 Definition -- 6.4.2 Geographical distribution -- 6.4.3 The causal organisms and their habitat -- 6.4.4 Epidemiology -- 6.4.5 Clinical manifestations -- 6.4.6 Differential diagnosis -- 6.4.7 Essential investigations and their interpretation -- 6.4.8 Management -- 6.5 Black piedra -- 6.5.1 Definition. 327 $a6.5.2 Geographical distribution. 330 $a"Fungal Infection: Diagnosis and Management," 4th Edition is a concise and up-to-date guide to the clinical manifestations, laboratory diagnosis and management of superficial, subcutaneous and systemic fungal infections.This highly acclaimed book has been extensively revised and updated throughout to ensure all drug and dosage recommendations are accurate and in agreement with current guidelines. A new chapter on infections caused by "Pneumocystis jirovecii" has been added. The book has been designed to enable rapid information retrieval and to help clinicians make informed decisions about diagnosis and patient management. Each chapter concludes with a list of recent key publications which have been carefully selected to facilitate efficient access to further information on specific aspects of fungal infections.Clinical microbiologists, infectious disease specialists, as well as dermatologists, hematologists and oncologists, can depend on this contemporary text for authoritative information and the background necessary to understand fungal infections. 606 $aMycoses$xDiagnosis 606 $aMycoses$xTreatment 615 0$aMycoses$xDiagnosis. 615 0$aMycoses$xTreatment. 676 $a616.9/69 700 $aRichardson$b M. D$0860654 701 $aWarnock$b D. W$0864389 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910815905603321 996 $aFungal infection$91929353 997 $aUNINA